ClinicalTrials.gg
CompletedNCT04302103Updated May 27, 2026

A Study of TACI(Transmembrane Activator and Calcium-modulator and Cyclophilin Ligand (CAML) Interactor)-Antibody Fusion Protein Injection (RC18) in Subjects With Systemic Myasthenia Gravis

A Phase 2 interventional study of RC18 160mg and RC18 240 mg in Systemic Myasthenia Gravis, sponsored by RemeGen Co., Ltd.. Completed at 24 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-05-27.

Sponsored by RemeGen Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
29
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 88 studies in Myasthenia Gravis with a site in China — 48 open to participants now, 60 under way, 17 of them phase 3. Myasthenia Gravis · China.

Enrollment
41st of 67
29 · median 40
Started
2020
with 8 others
Phase 2
5 of 88
2 open now
Registered
9th of 88
by date
Lead sponsor
3 of 88
RemeGen Co., Ltd.

Among the 88 studies in Myasthenia Gravis with a site in China, this one is the 41st largest by enrollment of the 67 interventional ones that give a count, is one of 9 that started in 2020, is one of 5 in phase 2, and was the 9th registered.

Myasthenia Gravis

331 studies on the registry are indexed under Myasthenia Gravis; 144 are open to participants now.

Browse Myasthenia Gravis studies →

Open to participants now

48 of the 88 studies in Myasthenia Gravis with a site in China are open now. Recruiting first, the newest first:

43 more — sign in →

All 48 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 88 studies in Myasthenia Gravis with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to initially observe the safety and effectivity of RC18 in Participants with systemic myasthenia gravis.

03

Conditions studied

  • Systemic Myasthenia Gravis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily signed ;
  2. Patient diagnosed with systemic myasthenia gravis according to The following conditions.
  3. Seropositive at screening for AChR(Acetylcholine receptor)-Ab or MuSK(Muscle specific tyrosine kinase)-Ab;
  4. MGFA(Myasthenia Gravis Foundation of America) Clinical classification Ⅱ-IIIb;
  5. QMG score≥8,and QMG score>2 in four or more items;
  6. Maintained any one of the stable standard treatment programs in the trial protocol.

Exclusion criteria

Exclusion Criteria:

  1. Combined diseases, such as systemic lupus erythematosus,rheumatoid arthritis, systemic sclerosis and so on,except for hypothyroidism and hyperthyroidism;
  2. Abnormal laboratory parameters need to be excluded, including but not limited to:
  3. agents except agents of standard treatment programs were used within one month prior to randomization.;
  4. Use of biological agents for targeted therapy within 6 months prior to randomization;
  5. Intravenous immunoglobulin therapy or plasma exchange therapy within 2 months before randomization;
  6. Active infection during screening(For example,herpes zoster, antibody positive,active tuberculosis,etc);
  7. Currently suffering from active hepatitis or severe liver lesions and history;
  8. Diabetics with poor blood sugar control:HbAlc>9.0% or FBG≥11.1mmol/L;
  9. Currently having a thymic tumor ,or had a thymectomy within 6 months prior to screening;
  10. Received within 3 months before randomization,or scheduled to administer vaccine during the trial;
  11. Malignant tumor patients;
  12. Allergic to human biological preparations;
  13. Have participated in any clinical trial within 28 days before randomization,or in 5 times half-life period of the drugs of any clinical trial(taking the longer time).
  14. Pregnant , lactating women and men or women who have birth plans during the research;
  15. Having alcohol or drug abuse that affect the experimental conditions;
  16. Investigator considers candidates not appropriating for the study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
29 participants (actual)

Study arms

  • Experimental
    RC18 160mg

    Patients received the test group RC18 160mg weekly administered subcutaneously for 24 times.

    Biological: RC18 160mg

  • Experimental
    RC18 240 mg

    Patients received the test group RC18 240mg weekly administered subcutaneously for 24 times.

    Biological: RC18 240 mg

Interventions

06

What researchers measure

Primary outcomes

  1. The average variation of QMG scores of the twenty-fourth week compared to the QMG scores of baseline

    QMG score=Quantitative Myasthenia Gravis Score

    Time frame: week 24

Secondary outcomes

  1. The average variation of clinical absolute score for myasthenia gravis of the twelfth and twenty-fourth weeks compared to Clinical absolute score for myasthenia gravis of baseline

    It is best that the assessors in each center are fixed during the study.

    Time frame: week 12,24

  2. The average variation of QMG score of the twelfth week compared to the OMG scores of baseline

    QMG score=Quantitative Myasthenia Gravis Score

    Time frame: week 12

07

Study locations

24 sites
  • The First Affiliated Hospital of Bengbu Medical University
    Bengbu, Anhui, China
  • The First Affiliated Hospital of USTC;Anhui Provincial Hospital
    Hefei, Anhui, China
  • Affiliated Hospital of Zunyi Medical University
    Zunyi, Guizhou, China
  • Nanyang First People's Hospital
    Nanyang, Henan, China
  • Xiangya Hospital of Central South University
    Changsha, Hunan, China
  • Jiangxi Provincial People's Hospital
    Nanchang, Jiangxi, China
  • The First Hospital of Jilin University
    Changchun, Jilin, China
  • The Second Affiliated Hospital of Dalian Medical University
    Dalian, Liaoning, China
  • The First Affiliated Hospital of Jinzhou Medical University
    Jinzhou, Liaoning, China
  • The Second Affiliated Hospital of Air Force Medical University
    Xi'an, Shaanxi, China
  • West China Hospital, Sichuan University
    Xi'an, Shaanxi, China
  • First Hospital of Shanxi Medical University
    Taiyuan, Shanxi, China
  • West China School of Medicine;West China Hospital of Sichuan University
    Chengdu, Sichuan, China
  • Affiliated Hospital of North Sichuan Medical College
    Nanchong, Sichuan, China
  • Zhejiang Provincial People's Hospital
    Hangzhou, Zhejiang, China
  • The First Affiliated Hospital of Wenzhou Medical University
    Wenzhou, Zhejiang, China
  • Beijing Anzhen Hospital, Capital Medical University
    Beijing, China
  • Beijing Hospital
    Beijing, China
  • Beijing Tiantan Hospital, Capital Medical University
    Beijing, China
  • Beijing Tongren Hospital, Capital Medical University
    Beijing, China
  • The First Affiliated Hospital of Chongqing Medical University
    Chongqing, China
  • The Third Affiliated Hospital, Sun Yat-sen University
    Guangzhou, China
  • The Second Hospital & Clinical medical school ; Lanzhou University
    Lanzhou, China
  • Huashan Hospital, Fudan University
    Shanghai, China
08

References and documents

Publications

  • Yin J, Zhao M, Xu X, Zhang M, Xu Z, Li Z, Qin X, Li Z, Zhao C, Zhou H, Ma Y, Cao W, Wang G, Lin Y, Zhang J, Zhang X, Cai H, Qian W, Wang Y, Zhang X, Liu G, Wang J, Qiu W, Min L, Li J, Deng H, Chu L, Zhang Y, Fang J. A multicenter, randomized, open-label, phase 2 clinical study of telitacicept in adult patients with generalized myasthenia gravis. Eur J Neurol. 2024 Aug;31(8):e16322. doi: 10.1111/ene.16322. Epub 2024 May 10. PubMed 38726639 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in Jan 2022, 18 months.

Of 22 phase 2 interventional studies under Myasthenia Gravis, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 30. This study's 18 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2020
First posted
Mar 10, 2020
StartActual
Jul 7, 2020
Primary completionActual
Jan 14, 2022
CompletionActual
Feb 11, 2022
Last update
May 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04302103
Lead sponsor
RemeGen Co., Ltd.
Responsible party
Sponsor
First posted
Mar 10, 2020
Start date
Jul 7, 2020
Primary completion
Jan 14, 2022
Completion
Feb 11, 2022
Last update
May 27, 2026

Study contacts

Xianhao Xu, M.D.
principal investigator · Beijing Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Telitacicept

Start the discussion